Quarterly report pursuant to Section 13 or 15(d)

Convertible Promissory Note Receivable

v3.23.1
Convertible Promissory Note Receivable
6 Months Ended
Dec. 31, 2022
Convertible Promissory Note Receivable [Abstract]  
Convertible Promissory Note Receivable

7.   Convertible Promissory Note Receivable

On October 1, 2020, the Company entered into a master services agreement with Safi Biosolutions, Inc. (“Safi”). In addition, the Company invested $1.5 million in Safi in the form of a convertible promissory note (the "Note"). The Note bears interest at the rate of 5% per annum and is convertible into shares of Safi’s common stock (as defined). Principal and accrued interest mature on October 1, 2023.  For both of the three months ended December 31, 2022 and 2021, interest income amounted to $19,000. For both of the six months ended December 31, 2022 and 2021, interest income amounted to $38,000. As of December 31, 2022 and June 30, 2022, the Note balance and accrued interest totaled $1,669,000 and $1,631,000, respectively.